Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

OBJECTIVE: Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from three phase 1 trials investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of the glucagon/GLP-1 r...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedrichsen, Martin Haljeta, Endahl, Lars, Kreiner, Frederik Flindt, Goldwater, Ronald, Kankam, Martin, Toubro, Søren, Nygård, Sune Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568562/
https://www.ncbi.nlm.nih.gov/pubmed/37690519
http://dx.doi.org/10.1016/j.molmet.2023.101801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568562/
https://www.ncbi.nlm.nih.gov/pubmed/37690519
http://dx.doi.org/10.1016/j.molmet.2023.101801

Ejemplares similares